1,458,259 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, HoldingsChannel reports. The firm bought 1,458,259 shares of the medical equipment provider’s stock, valued at approximately $125,542,000.

Other large investors have also recently added to or reduced their stakes in the company. DV Equities LLC bought a new position in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Tacita Capital Inc acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth $26,000. Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet in the 4th quarter worth $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $31,000. Finally, Elevation Wealth Partners LLC lifted its holdings in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 229 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $100.25 on Wednesday. The company’s 50 day moving average price is $93.11 and its 200 day moving average price is $91.22. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The company has a market capitalization of $19.12 billion, a PE ratio of 24.39, a PEG ratio of 2.75 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.28% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ZBH. Truist Financial lifted their price target on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Sanford C. Bernstein lifted their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Citigroup cut their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Canaccord Genuity Group upped their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Finally, Royal Bank Of Canada raised their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.